Virax Biolabs Group Limit... (VRAX)
1.06
0.04 (3.92%)
At close: Apr 15, 2025, 3:59 PM
1.00
-5.66%
After-hours: Apr 15, 2025, 06:07 PM EDT
3.92% (1D)
| Bid | 0.97 |
| Market Cap | 4.6M |
| Revenue (ttm) | 84.87K |
| Net Income (ttm) | -6.58M |
| EPS (ttm) | -2.61 |
| PE Ratio (ttm) | -0.41 |
| Forward PE | -1.08 |
| Analyst | Buy |
| Ask | 1.19 |
| Volume | 75,593 |
| Avg. Volume (20D) | 263,318 |
| Open | 0.97 |
| Previous Close | 1.02 |
| Day's Range | 0.97 - 1.09 |
| 52-Week Range | 0.60 - 9.00 |
| Beta | 1.80 |
About VRAX
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, su...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 21, 2022
Employees 17
Stock Exchange NASDAQ
Ticker Symbol VRAX
Website https://viraxbiolabs.com
Analyst Forecast
According to 1 analyst ratings, the average rating for VRAX stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 183.02% from the latest price.
Stock Forecasts5 months ago
+50%
Virax Biolabs shares are trading higher after the ...
Unlock content with
Pro Subscription
7 months ago
+9.65%
Virax Biolabs shares are trading higher after the company announced it extended its existing exclusive distribution agreement with Cosmos Health to market Mpox in real time through its PCR detection kits.
